- UK Prime Minister Says British COVID Variant May Be More Deadly
- FDA Approves First Once-a-Month HIV Therapy
- Half of Americans Still Not Wearing Masks When Out in Public: Poll
- For Maximum Effectiveness, De-Stress and Get Healthy Before Your COVID Shot
- AHA News: Anxiety Is Linked With Smoking – But How Is Still Hazy
- Biden Warns of 500,000 COVID Deaths by February
- Health Highlights: Jan. 22, 2021
- For Rising Number of People, Obesity Is a Literal Headache
- Even When Cancer Is in Remission, Patients’ Risks of Severe COVID Rise
- Exercise Doesn’t Boost Health If You Stay Obese, Study Finds
Tretten Approved for Genetic Clotting Disorder
Tretten (coagulation factor XIII A-Subunit recombinant) has been approved by the U.S. Food and Drug Administration to treat a very rare blood clotting disorder called congenital Factor XIII A-Subunit deficiency.
People with the genetic disorder do not make enough Factor XIII, a blood component that promotes clotting. Tretten, a human recombinant produced in yeast cells, makes up for this deficiency, which could otherwise be life threatening, the FDA said Monday in a news release.
Tretten was evaluated in a clinical study of 77 people with the disorder. Administered monthly, it was effective in preventing bleeding in 90 percent of recipients. Side effects included headache, extremity pain and pain at the injection site. No study participant developed abnormal clotting, the FDA said.
The product was developed and is produced by Novo Nordisk, based in Denmark.
More information
To learn more about this disorder, visit the National Hemophilia Foundation.
Source: HealthDay
